These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

240 related articles for article (PubMed ID: 11895066)

  • 1. Risedronate for the prevention and treatment of corticosteroid-induced osteoporosis.
    Dougherty JA
    Ann Pharmacother; 2002 Mar; 36(3):512-6. PubMed ID: 11895066
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and safety of daily risedronate in the treatment of corticosteroid-induced osteoporosis in men and women: a randomized trial. European Corticosteroid-Induced Osteoporosis Treatment Study.
    Reid DM; Hughes RA; Laan RF; Sacco-Gibson NA; Wenderoth DH; Adami S; Eusebio RA; Devogelaer JP
    J Bone Miner Res; 2000 Jun; 15(6):1006-13. PubMed ID: 10841169
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Risedronate increases bone density and reduces vertebral fracture risk within one year in men on corticosteroid therapy.
    Reid DM; Adami S; Devogelaer JP; Chines AA
    Calcif Tissue Int; 2001 Oct; 69(4):242-7. PubMed ID: 11730260
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Risedronate therapy prevents corticosteroid-induced bone loss: a twelve-month, multicenter, randomized, double-blind, placebo-controlled, parallel-group study.
    Cohen S; Levy RM; Keller M; Boling E; Emkey RD; Greenwald M; Zizic TM; Wallach S; Sewell KL; Lukert BP; Axelrod DW; Chines AA
    Arthritis Rheum; 1999 Nov; 42(11):2309-18. PubMed ID: 10555025
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prevention of bone loss with risedronate in glucocorticoid-treated rheumatoid arthritis patients.
    Eastell R; Devogelaer JP; Peel NF; Chines AA; Bax DE; Sacco-Gibson N; Nagant de Deuxchaisnes C; Russell RG
    Osteoporos Int; 2000; 11(4):331-7. PubMed ID: 10928223
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of risedronate treatment on bone density and vertebral fracture in patients on corticosteroid therapy.
    Wallach S; Cohen S; Reid DM; Hughes RA; Hosking DJ; Laan RF; Doherty SM; Maricic M; Rosen C; Brown J; Barton I; Chines AA
    Calcif Tissue Int; 2000 Oct; 67(4):277-85. PubMed ID: 11000340
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bisphosphonate risedronate prevents bone loss in women with artificial menopause due to chemotherapy of breast cancer: a double-blind, placebo-controlled study.
    Delmas PD; Balena R; Confravreux E; Hardouin C; Hardy P; Bremond A
    J Clin Oncol; 1997 Mar; 15(3):955-62. PubMed ID: 9060533
    [TBL] [Abstract][Full Text] [Related]  

  • 8. WITHDRAWN: Risedronate for the prevention and treatment of postmenopausal osteoporosis.
    Cranney A; Adachi JD; Guyatt G; Papaioannou A; Robinson VA; Shea BJ; Tugwell P; Waldegger LM; Weaver B; Wells G; Zytaruk N
    Cochrane Database Syst Rev; 2007 Jul; (1):CD004523. PubMed ID: 17636764
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Risedronate: a review of its pharmacological properties and clinical use in resorptive bone disease.
    Dunn CJ; Goa KL
    Drugs; 2001; 61(5):685-712. PubMed ID: 11368289
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Risedronate: clinical usage.
    Chapurlat RD; Delmas PD
    Int J Clin Pract; 2001 May; 55(4):275-8. PubMed ID: 11406915
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Risedronate: a clinical review.
    Crandall C
    Arch Intern Med; 2001 Feb; 161(3):353-60. PubMed ID: 11176760
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Risedronate: a new oral bisphosphonate.
    Umland EM; Boyce EG
    Clin Ther; 2001 Sep; 23(9):1409-21. PubMed ID: 11589256
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Risedronate for the prevention of fractures in postmenopausal osteoporosis.
    Sickels JM; Nip CS
    Ann Pharmacother; 2002 Apr; 36(4):664-70. PubMed ID: 11918518
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A comparison of the effect of risedronate and etidronate on lumbar bone mineral density in Japanese patients with osteoporosis: a randomized controlled trial.
    Fukunaga M; Kushida K; Kishimoto H; Shiraki M; Taketani Y; Minaguchi H; Inoue T; Morita R; Morii H; Yamamoto K; Ohashi Y; Orimo H;
    Osteoporos Int; 2002 Dec; 13(12):971-9. PubMed ID: 12459940
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Risedronate increases bone mineral density and reduces the vertebral fracture incidence in postmenopausal women.
    Reginster JY
    Clin Exp Rheumatol; 2001; 19(2):121-2. PubMed ID: 11326471
    [No Abstract]   [Full Text] [Related]  

  • 16. Risedronate preserves bone architecture in early postmenopausal women in 1 year as measured by three-dimensional microcomputed tomography.
    Dufresne TE; Chmielewski PA; Manhart MD; Johnson TD; Borah B
    Calcif Tissue Int; 2003 Nov; 73(5):423-32. PubMed ID: 12964065
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Risedronate once a week.
    White NJ; Perry CM
    Treat Endocrinol; 2003; 2(6):415-20; discussion 421. PubMed ID: 15981945
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Risedronate reverses bone loss in postmenopausal women with low bone mass: results from a multinational, double-blind, placebo-controlled trial. BMD-MN Study Group.
    Fogelman I; Ribot C; Smith R; Ethgen D; Sod E; Reginster JY
    J Clin Endocrinol Metab; 2000 May; 85(5):1895-900. PubMed ID: 10843171
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Is the increase in osteoporosis prevention a result of the audit?
    Naunton M
    Clin Neurol Neurosurg; 2006 Oct; 108(7):718-9. PubMed ID: 16621242
    [No Abstract]   [Full Text] [Related]  

  • 20. Relationship between changes in BMD and nonvertebral fracture incidence associated with risedronate: reduction in risk of nonvertebral fracture is not related to change in BMD.
    Watts NB; Geusens P; Barton IP; Felsenberg D
    J Bone Miner Res; 2005 Dec; 20(12):2097-104. PubMed ID: 16294263
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.